PDS0101 Plus Pembrolizumab Yields Positive Survival Results in HNSCC
Written by
Cancer Network
Published
0
comments
0
min
The median overall survival was 39.3 months with PDS0101 plus pembrolizumab in those with frontline recurrent or metastatic head and neck squamous cell carcinoma.